These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

786 related items for PubMed ID: 31923858

  • 1. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
    Wang R, Yu S, Zhao X, Chen Y, Yang B, Wu T, Hao C, Zhao D, Cheng M.
    Eur J Med Chem; 2020 Feb 15; 188():112024. PubMed ID: 31923858
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.
    Wang R, Chen Y, Zhao X, Yu S, Yang B, Wu T, Guo J, Hao C, Zhao D, Cheng M.
    Eur J Med Chem; 2019 Dec 01; 183():111716. PubMed ID: 31550660
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Design, synthesis and biological evaluation of ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors.
    Xie H, Lin X, Zhang Y, Tan F, Chi B, Peng Z, Dong W, An D.
    Bioorg Med Chem Lett; 2020 Nov 01; 30(21):127459. PubMed ID: 32784087
    [Abstract] [Full Text] [Related]

  • 6. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
    Farghaly AM, AboulWafa OM, Baghdadi HH, Abd El Razik HA, Sedra SMY, Shamaa MM.
    Bioorg Chem; 2021 Oct 01; 115():105208. PubMed ID: 34365057
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M, Kassab AE, Zaher AF, Mahmoud Z.
    Anticancer Agents Med Chem; 2019 Oct 01; 19(11):1368-1381. PubMed ID: 31038080
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis, and biological evaluation of novel covalent inhibitors targeting focal adhesion kinase.
    Chen T, Liu Y, Shi M, Tang M, Si W, Yuan X, Wen Y, Chen L.
    Bioorg Med Chem Lett; 2021 Dec 15; 54():128433. PubMed ID: 34757216
    [Abstract] [Full Text] [Related]

  • 10. Design, synthesis and biological evaluation of novel 2,4-bismorpholinothieno[3,2-d]pyrimidine and 2-morpholinothieno[3,2-d]pyrimidinone derivatives as potent antitumor agents.
    Ye T, Han Y, Wang R, Yan P, Chen S, Hou Y, Zhao Y.
    Bioorg Chem; 2020 Jun 15; 99():103796. PubMed ID: 32283346
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Synthesis, anticancer activity and effects on cell cycle profile and apoptosis of novel thieno[2,3-d]pyrimidine and thieno[3,2-e] triazolo[4,3-c]pyrimidine derivatives.
    Kandeel MM, Refaat HM, Kassab AE, Shahin IG, Abdelghany TM.
    Eur J Med Chem; 2015 Jan 27; 90():620-32. PubMed ID: 25499930
    [Abstract] [Full Text] [Related]

  • 14. Design, Synthesis, In Silico and In Vitro Evaluation of Novel Pyrimidine Derivatives as EGFR Inhibitors.
    Matada GSP, Abbas N, Dhiwar PS, Basu R, Devasahayam G.
    Anticancer Agents Med Chem; 2021 Jan 27; 21(4):451-461. PubMed ID: 32698735
    [Abstract] [Full Text] [Related]

  • 15. Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities.
    Su Y, Li R, Ning X, Lin Z, Zhao X, Zhou J, Liu J, Jin Y, Yin Y.
    Eur J Med Chem; 2019 Sep 01; 177():32-46. PubMed ID: 31129452
    [Abstract] [Full Text] [Related]

  • 16. Synthesis and in vitro antitumor evaluation of new thieno[2,3-d]pyrimidine derivatives as EGFR and DHFR inhibitors.
    Fouad MM, Ghabbour HA, Shehata IA, El-Ashmawy MB.
    Bioorg Chem; 2024 Jul 01; 148():107401. PubMed ID: 38749115
    [Abstract] [Full Text] [Related]

  • 17. Thieno[2,3-d]pyrimidin-4(3H)-one Derivatives of Benzimidazole as Potential Anti- Breast Cancer (MDA-MB-231, MCF-7) Agents.
    Dimov S, Mavrova AT, Yancheva D, Nikolova B, Tsoneva I.
    Anticancer Agents Med Chem; 2021 Jul 01; 21(11):1441-1450. PubMed ID: 32698751
    [Abstract] [Full Text] [Related]

  • 18. Design, synthesis and biological evaluation of 1H-pyrazolo [3,4-d]pyrimidine derivatives as PAK1 inhibitors that trigger apoptosis, ER stress and anti-migration effect in MDA-MB-231 cells.
    Zhang J, Zou L, Tang P, Pan D, He Z, Yao D.
    Eur J Med Chem; 2020 May 15; 194():112220. PubMed ID: 32222676
    [Abstract] [Full Text] [Related]

  • 19. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
    Luo G, Ma Y, Liang X, Xie G, Luo Y, Zha D, Wang S, Yu L, Zheng X, Wu W, Zhang C.
    Bioorg Chem; 2020 Nov 15; 104():104356. PubMed ID: 33142417
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Elmetwally SA, Saied KF, Eissa IH, Elkaeed EB.
    Bioorg Chem; 2019 Jul 15; 88():102944. PubMed ID: 31051400
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.